Company Profile

Cell Valley Group was founded by a group of passionate and visionary Chinese scientists from the United States and Hong Kong. The founding team members come from world-renowned universities such as Harvard University, Cornell University, Columbia University, and the University of California, San Diego, possessing exceptional research capabilities and an international perspective. The cutting-edge research concepts, profound academic foundation, and strong innovation capabilities provided by these top universities have laid a solid foundation for the development of Cell Valley Group.

Currently, Cell Valley Group has established cell production centers, viral vector production centers, and a northern R&D center in Pingshan District, Shenzhen; Torch Development Zone, Zhongshan; and Daxing District, Beijing, respectively. The group owns five wholly-owned subsidiaries—Shenzhen Cell Valley, Shenzhen-Hong Kong Cell Valley, Guangzhou Cell Valley, Guangdong Junhou Biotechnology, and Beijing Jingshen Cell Valley—forming an industrial layout covering South and North China. The group has built over 10,000 square meters of GMP-grade production workshops and high-standard R&D laboratories, and owns two internationally compliant P2-level biosafety laboratories in Shenzhen and Zhongshan. Its core technological advantages include: the first clinical-grade retroviral vector GMP industrial production line in China (completed in 2020), a library of over 100 types of clinical-grade viral vectors, the internationally leading eVLP-KOKI gene editing and delivery system, and the first GMP-grade natural killer cell (NK cell) and γδT cell exosome production line in China to achieve large-scale production, placing it at the forefront of the industry.

On September 7, 2024, the Ministry of Commerce, the National Health Commission, and the National Medical Products Administration jointly issued the "Notice on Carrying out Pilot Work on Expanding Opening-up in the Medical Field," which for the first time allows foreign-invested enterprises in free trade zones such as Guangdong to engage in research and application of human stem cell, gene diagnosis, and treatment-related technologies. As the first overseas (Hong Kong) invested enterprise to benefit from this policy, Cell Valley Group officially established Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. in the Qianhai Free Trade Zone of Shenzhen in February 2025, with a registered capital of 100 million RMB, and over 20% of its employees are from Hong Kong and the United States. Shenzhen-Hong Kong Cell Valley, serving as the group's international business and medical services headquarters, targets the Guangdong-Hong Kong-Macao Greater Bay Area, Southeast Asia, and European and American markets.  It focuses on high-end cell and gene therapy solutions and actively expands into consumer healthcare fields such as health and wellness, medical aesthetics, and anti-aging, forming an innovative business model driven by both "medical services + consumer healthcare." Leveraging the group's core technologies and processes in clinical-grade viral vector preparation, gene editing and delivery systems, stem cell and immune cell platforms, and large-scale industrial production of various exosomes, Shenzhen-Hong Kong Cell Valley is committed to building a globally leading one-stop service platform for cell and gene therapy and health management.

The group's production and R&D headquarters, Shenzhen Cell Valley, has received numerous accolades, including: Shenzhen Biomedical Industry Major Public Service Platform, National Cell Industry Key Common Technology Engineering Research Center – Viral Vector Common Technology Research Platform, Shenzhen High-tech Zone Development Special Plan Innovation Platform Achievement Industrialization Base, Vice President Unit of China Food and Drug Enterprise Quality and Safety Promotion Association, Shenzhen Medical Research Special Fund Support Unit, Vice Chairman Unit of Shenzhen Biomedical Industry Industry-Education Alliance, 2023 Pingshan District Biomedical Field "Julong Leading Talent" Class D High-Growth Enterprise, Technology-based Small and Medium-sized Enterprise, Innovative Small and Medium-sized Enterprise, and Shenzhen Pingshan District University Student Internship Base. It is also one of Shenzhen's newly announced "20+8" strategic emerging industry projects. Shenzhen Cell Valley's "One-Stop Cell and Gene Therapy CRO/CDMO Service Platform – South China Cell Factory" project was approved as a key project by Shenzhen in 2022. Shenzhen Cell Valley has built a multi-functional integrated production and service platform with a total area of 8,000 square meters, including 4,000 square meters of "C+A, B+A" clean workshops. This platform is equipped with GMP-compliant retroviral vector and cell product industrial production lines, GLP-compliant process development and analysis laboratories, and office areas.